Persistent elevation of hepatocyte growth factor activator inhibitors in cholangiopathies affects liver fibrosis and differentiation

Hepatology. 2012 Jan;55(1):161-72. doi: 10.1002/hep.24657. Epub 2011 Nov 16.

Abstract

Alteration of cell surface proteolysis has been proposed to play a role in liver fibrosis, a grave complication of biliary atresia (BA). In this study we investigated the roles of hepatocyte growth factor activator inhibitor (HAI)-1 and -2 in the progression of BA. The expression levels of HAI-1 and -2 were significantly increased in BA livers compared with those in neonatal hepatitis and correlated with disease progression. In BA livers, HAI-1 and -2 were coexpressed in cells involved in ductular reactions. In other selective cholangiopathies, ductular cells positive for HAI-1 or HAI-2 also increased in number. Inflammatory cytokines, growth factors, and bile acids differentially up-regulated expression of HAI-1 and -2 transcripts in fetal liver cells and this induction could be antagonized by a cyclooxygenase-2 inhibitor. Conditioned media from cell lines stably overexpressing HAI-1 or HAI-2 enhanced the fibrogenic activity of portal fibroblasts and stellate cells, suggesting that both proteins might be involved in liver fibrosis. Because HAI-1 and -2 colocalized in ductular reactions sharing similar features to those observed during normal liver development, we sought to investigate the role of HAI-1 and -2 in cholangiopathies by exploring their functions in fetal liver cells. Knockdown of HAI-1 or HAI-2 promoted bidirectional differentiation of hepatoblast-derived cells. In addition, we showed that the hepatocyte growth factor activator, mitogen-activated protein kinase kinase 1, and phosphatidylinositol 3-kinase signaling pathways were involved in hepatic differentiation enhanced by HAI-2 knockdown.

Conclusion: HAI-1 and -2 are overexpressed in the liver in cholangiopathies with ductular reactions and are possibly involved in liver fibrosis and hepatic differentiation; they could be investigated as disease markers and potential therapeutic targets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation / physiology
  • Cell Line
  • Cholestasis / pathology*
  • Cholestasis / physiopathology
  • Female
  • Fibroblasts / cytology
  • Hepatic Stellate Cells / cytology
  • Hepatitis / congenital
  • Hepatitis / pathology*
  • Hepatitis / physiopathology
  • Hepatocytes / cytology
  • Humans
  • Infant
  • Infant, Newborn
  • Liver Cirrhosis / congenital
  • Liver Cirrhosis / pathology*
  • Male
  • Membrane Glycoproteins / genetics*
  • Membrane Glycoproteins / metabolism
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Proteinase Inhibitory Proteins, Secretory / genetics*
  • Proteinase Inhibitory Proteins, Secretory / metabolism
  • Rats
  • Signal Transduction / physiology
  • Stem Cells / cytology
  • Stem Cells / physiology

Substances

  • Membrane Glycoproteins
  • Membrane Proteins
  • Proteinase Inhibitory Proteins, Secretory
  • SPINT1 protein, human
  • SPINT2 protein, human
  • Spint1 protein, mouse
  • Spint2 protein, mouse